Compare SIEB & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | RANI |
|---|---|---|
| Founded | 1886 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 134.6M |
| IPO Year | N/A | 2021 |
| Metric | SIEB | RANI |
|---|---|---|
| Price | $3.58 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 26.9K | ★ 2.6M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $90,289,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | $19.56 | ★ N/A |
| Revenue Growth | ★ 8.32 | N/A |
| 52 Week Low | $2.08 | $0.39 |
| 52 Week High | $5.77 | $3.87 |
| Indicator | SIEB | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 41.87 |
| Support Level | $3.45 | $1.33 |
| Resistance Level | $3.93 | $1.53 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 21.12 | 20.00 |
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.